Analysis of a wide array of primary human T-ALLs and PDX human:mouse models suggests that the combination of temsirolimus and dasatinib treatment will be efficacious for a large fraction of human T-ALLs.112 In light of this data, several phase 1 and 2 clinical trials in T-ALL have been started to test mTOR inhibitors in R/R T and B-ALL patients in combination with corticosteroids and other drugs used during the chemotherapy regimen (NCT01403415, NCT03740334, NCT01614197, NCT01184885). This evidence concerns the gene MTOR and acute lymphoblastic leukemia.